Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.

ABSTRACT:

Importance

Migraine with aura may respond differently to therapies than migraine without aura. Individuals with migraine with aura have an elevated vascular risk, necessitating a safety assessment of migraine preventive treatments in this patient subgroup.

Objective

To assess the efficacy and safety profiles of erenumab in patients with migraine with aura.

Design, setting, and participants

This post hoc secondary analysis evaluated 4 double-blind, placebo-controlled randomized clinical trials that were conducted in treatment centers in North America, Europe, Russia, and Turkey between August 6, 2013, and November 12, 2019. Participants were adults aged 18 to 65 years with episodic migraine or chronic migraine and were randomized to receive either erenumab or placebo.<

SUBMITTER: Ashina M 

PROVIDER: S-EPMC8689443 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature